medecolМедицина и экологияMedicine and ecology2305-60452305-6053Карагандинский медицинский университетmedecol-222Research ArticleОРГАНИЗАЦИЯ И ЭКОНОМИКА ЗДРАВООХРАНЕНИЯORGANIZATION AND ECONOMICS OF HEALTHФАРМАКОЭКОНОМИЧЕСКАЯ ЦЕЛЕСООБРАЗНОСТЬ ИСПОЛЬЗОВАНИЯ ПРЕПАРАТА «СУЛЬТОФАЙ®» (ИНСУЛИН ДЕГЛУДЕК 100 ЕД + ЛИРАГЛУТИД 3,6 МГ) ДЛЯ ЛЕЧЕНИЯ САХАРНОГО ДИАБЕТА ВТОРОГО ТИПА В УСЛОВИЯХ ПРИВЫЧНОЙ КЛИНИЧЕСКОЙ ПРАКТИКИPHARMACOECONOMIC FEASIBILITY OF USING THE DRUG «XYLTOPHY®» (INSULIN DEGLUDEC U100 + LIRAGLUTIDE 3,6 MG) FOR THE TREATMENT OF THE SECOND TYPE DIABETES MELIUS IN CONVENTIONAL CLINICAL PRACTICEГуляевА. Е.GulyayevA. Ye.noemail@neicon.ruЖаугашеваС. К.ZhaugashevaS. K.noemail@neicon.ruКимТ. В.KimT. V.noemail@neicon.ruПивеньЛ. И.PivenL. I.noemail@neicon.ruНазарбаев УниверситетКазахстанNazarbayev UniversityKazakhstanМедицинский университет КарагандыКазахстанKaraganda medical universityKazakhstan202007092021038895Copyright © Гуляев А.Е., Жаугашева С.К., Ким Т.В., Пивень Л.И., 20212021Гуляев А.Е., Жаугашева С.К., Ким Т.В., Пивень Л.И.Gulyayev A.Y., Zhaugasheva S.K., Kim T.V., Piven L.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://medecol.qmu.kz/jour/article/view/222

Целью проведенного исследования была оценка экономической эффективности препарата «Сультофай®» (инсулин деглудек 100 ЕД + лираглутид 3,6 мг (IDegLira) по сравнению с типичной базис-болюсной терапией (базальный инсулин гларгин U100 + болюсный инсулин аспарт) у больных сахарным диабетом второго типа. Затраты, связанные со стоимостью лекарственных средств и менеджмента, были зафиксированы с точки зрения плательщика здравоохранения в ценах 2020 г. в тенге. Дисконтирование не применялось. Установлено, что использование препарата «Сультофай®» связано с большими затратами собственно на приобретение лекарственных средств (469 525,29 тенге против 276 988,24 тенге на пациента в год), но это было полностью компенсировано меньшими затратами на коррекцию эпизодов гипогликемии и снижением стоимости менеджмента. Все это приводит к тому, что применение препарата «Сультофай®» ассоциируется с более низким годовым уровнем затрат (497 759,29 против 390 407,24 тенге) по сравнению с затратами, необходимыми при использовании инсулина гларгин U100 + инсулин аспарт. Анализ чувствительности полностью подтверждают результаты базового анализа. Для плательщика замена стандартной базисно-болюсной терапии инсулином гларгин U100 + инсулин аспарт на терапию препаратом «Сультофай®» может дать экономию бюджета здравоохранения около 7,5 млрд тенге в течение первых трех лет.

The present study aimed to evaluate the cost - effectiveness of the drug «Xyltophy®» (insulin degludec U100 + liraglutide 3,6 mg, IDegLira) compared with typical basic-bolus therapy (basal insulin glurgin U100 plus bolus insulin aspart) in patients with type 2 diabetes mellitus. The costs associated with the cost of medicines and management were recorded from the period of view of the health care payer in 2020 prices in tenge. Discounting was not applied. It found that the use of the drug «Xyltophy®» is associated with high costs for the purchase of medicines (469 525,29 against 276 988,24 tenge), but this was fully compensated by lower costs for correction of episodes by hypoglycemia and in reducing the cost of management. All this leads to the fact that use of the drug «Xyltophy®» is associated with a lower annual cost level (497 759,29 against 390 407,24 tenge) compared with the costs required when using insulin glargin U100 plus insulin aspart. The sensitivity analysis fully confirms the results of basic analysis. For the payer, the replacement of the standard basic - bolus therapy with insulin glargin U100 plus insulin aspart for the therapy drug «Xyltophy®» can save the health care budget about 7,5 billion tenge in the first three year.

Сультофай®фармакоэкономикаминимизация затрат на лечениевлияние на бюджет«Xyltophy®»pharmacoeconomicsminimization of treatment costsbudget impactReferencesAmerican Diabetes Association Standards of medical care in diabetes-2016 abridged for primary care providers //Clin. Diabetes. - 2016. - V. 356. - P. 3-21.American Diabetes Association Standards of medical care in diabetes-2016 abridged for primary care providers //Clin. Diabetes. - 2016. - V. 356. - P. 3-21.Bagust A. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data /A. Bagust, S. Beale //Health Econ. - 2005. - V. 14 (3). - P. 217-230.Bagust A. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data /A. Bagust, S. Beale //Health Econ. - 2005. - V. 14 (3). - P. 217-230.Centers for Disease Control and Prevention. National diabetes statistics report. Estimates of Diabetes and its Burden in the United States, 2017. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html.Centers for Disease Control and Prevention. National diabetes statistics report. Estimates of Diabetes and its Burden in the United States, 2017. https://www.cdc.gov/diabetes/data/statistics/statistics-report.html.Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDeg-Lira) in People with Type 2 Diabetes /S. Harris, M. J. Abrahamson, A. Ceriello et al. //Drugs. - 2020. -V. 80 (2). - P. 147-165.Clinical Considerations When Initiating and Titrating Insulin Degludec/Liraglutide (IDeg-Lira) in People with Type 2 Diabetes /S. Harris, M. J. Abrahamson, A. Ceriello et al. //Drugs. - 2020. -V. 80 (2). - P. 147-165.Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system /M. Psota, M. B. Psenkova, N. Racekova et al. //Clinicoecon. Outcomes. Res. - 2017. - V. 12. - P. 749-762.Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system /M. Psota, M. B. Psenkova, N. Racekova et al. //Clinicoecon. Outcomes. Res. - 2017. - V. 12. - P. 749-762.Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic /M. Kvapil, M. Prazny, P. Holik et al. // Diabetes Ther. - 2017. - V. 8 (6). - P. 1331-1347.Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic /M. Kvapil, M. Prazny, P. Holik et al. // Diabetes Ther. - 2017. - V. 8 (6). - P. 1331-1347.Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial /L. K. Billings, A. Doshi, D. Gouet et al. //Diabetes Care. - 2018. - V. 41(5). - P. 1009-1016.Efficacy and safety of IDegLira versus basal-bolus insulin therapy in patients with type 2 diabetes uncontrolled on metformin and basal insulin: the DUAL VII randomized clinical trial /L. K. Billings, A. Doshi, D. Gouet et al. //Diabetes Care. - 2018. - V. 41(5). - P. 1009-1016.Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study /M. Ridderstr§le, L. M. Evans, H. H. Jensen et al. //Health Qual. Life. Outcomes. - 2016. - V. 14. - P. 13.Estimating the impact of changes in HbA1c, body weight and insulin injection regimen on health related quality-of-life: a time trade off study /M. Ridderstr§le, L. M. Evans, H. H. Jensen et al. //Health Qual. Life. Outcomes. - 2016. - V. 14. - P. 13.Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/ liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence /P. M. Raya, F. J. A. Blasco, B. Hunt et al. Diabetes Obes. Metab. - 2019. - V. 21 (6). - P. 1349-1356.Evaluating the long-term cost-effectiveness of fixed-ratio combination insulin degludec/ liraglutide (IDegLira) for type 2 diabetes in Spain based on real-world clinical evidence /P. M. Raya, F. J. A. Blasco, B. Hunt et al. Diabetes Obes. Metab. - 2019. - V. 21 (6). - P. 1349-1356.Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets /A. J. Cannon, A. Bargiota, L. Billings //J. Manag. Care. Spec. Pharm. - 2020. -V. 26 (2). - P. 143-153.Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Basal Insulin and Basal-Bolus Therapy in Patients with Type 2 Diabetes Based on Attainment of Clinically Relevant Treatment Targets /A. J. Cannon, A. Bargiota, L. Billings //J. Manag. Care. Spec. Pharm. - 2020. -V. 26 (2). - P. 143-153.Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries / M. Evans, K. Khunti, M. Mamdani et al. //Health Qual. Life Outcomes. - 2013. - V. 11 (1). - P. 90.Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries / M. Evans, K. Khunti, M. Mamdani et al. //Health Qual. Life Outcomes. - 2013. - V. 11 (1). - P. 90.https://24.kz/ru/news/social/item/318 826-chislo-bolnykh-sakharnym-diabetom-v-kazakhstane-dostiglo-340-000https://24.kz/ru/news/social/item/318 826-chislo-bolnykh-sakharnym-diabetom-v-kazakhstane-dostiglo-340-000https://egov.kz/cms/ru/law/list/V1900019309https://egov.kz/cms/ru/law/list/V1900019309https://total.kz/ru/news/zhizn/diabet_grozit_kazhdomu_chetvertomu_kazahstant-su_date_2019_04_25_16_17_29https://total.kz/ru/news/zhizn/diabet_grozit_kazhdomu_chetvertomu_kazahstant-su_date_2019_04_25_16_17_29https: / / www.inal maty.kz/ news/2411 052/pocemu-diabet-nazyvaut-dorogim-udovol-stviem-dla-kazahstanahttps: / / www.inal maty.kz/ news/2411 052/pocemu-diabet-nazyvaut-dorogim-udovol-stviem-dla-kazahstanaIdeglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S. /M. Dempsey, M. Mocarski, J. Langer, B. Hunt //Endocr. Pract. - 2018. - V. 24 (9). - P. 796-804.Ideglira is Associated With Improved Short-Term Clinical Outcomes and Cost Savings Compared with Insulin Glargine U100 Plus Insulin Aspart in the U.S. /M. Dempsey, M. Mocarski, J. Langer, B. Hunt //Endocr. Pract. - 2018. - V. 24 (9). - P. 796-804.International Diabetes Federation (2006): Diabetes Atlas, third editionInternational Diabetes Federation (2006): Diabetes Atlas, third editionInternational Diabetes Federation, 2015 URL: http://www.diabetesatlas.org. Первый глобальный доклад ВОЗ по проблеме сахарного диабета, 2016 г. http://www.who.int/eInternational Diabetes Federation, 2015 URL: http://www.diabetesatlas.org. Первый глобальный доклад ВОЗ по проблеме сахарного диабета, 2016 г. http://www.who.int/eLong-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US /M. Dempsey, M. Mocarski, J. Langer, B. Hunt //J. Med. Econ. - 2018. - V. 21(11). - P. 1 110-1 118.Long-term cost-effectiveness analysis shows that IDegLira is associated with improved outcomes and lower costs compared with insulin glargine U100 plus insulin aspart in the US /M. Dempsey, M. Mocarski, J. Langer, B. Hunt //J. Med. Econ. - 2018. - V. 21(11). - P. 1 110-1 118.Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial /H. W. Rodbard, B. W. Bode, S. B. Harris et al. //Diabet. Med. - 2017. - V. 34 (2). -P. 189-196.Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naive people with Type 2 diabetes: the DUAL IV trial /H. W. Rodbard, B. W. Bode, S. B. Harris et al. //Diabet. Med. - 2017. - V. 34 (2). -P. 189-196.The management of type 2 diabetes with fixed-ratio combination insulin degludec/ liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A shortterm cost-effectiveness analysis in the UK setting / R. Drummond, S. Malkin, M. Du Preez et al. // Diabetes Obes. Metab. - 2018. - V. 20 (10). - P. 2371-2378.The management of type 2 diabetes with fixed-ratio combination insulin degludec/ liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A shortterm cost-effectiveness analysis in the UK setting / R. Drummond, S. Malkin, M. Du Preez et al. // Diabetes Obes. Metab. - 2018. - V. 20 (10). - P. 2371-2378.Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy /J. Pohlmann, R. Montagnoli, G. Lastoria et al. //Clinicoecon. Outcomes. Res. - 2019. - V. 7. - P. 605-614.Value For Money In The Treatment Of Patients With Type 2 Diabetes Mellitus: Assessing The Long-Term Cost-Effectiveness Of IDegLira Versus iGlarLixi In Italy /J. Pohlmann, R. Montagnoli, G. Lastoria et al. //Clinicoecon. Outcomes. Res. - 2019. - V. 7. - P. 605-614.Warren M. Clinical Use of IDegLira: Initiation to Titration After Basal Insulin /Warren, D. Steel //Clin. Diabetes. - 2020. - V. 38 (1). - P. 62-70.Warren M. Clinical Use of IDegLira: Initiation to Titration After Basal Insulin /Warren, D. Steel //Clin. Diabetes. - 2020. - V. 38 (1). - P. 62-70.

The authors declare that there are no conflicts of interest present.